ASCLETIS-B (1672.HK)
Market: HKEX |
Currency: HKD
Address: Building D
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.
Show more
📈 ASCLETIS-B Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$12.01
-
Upside/Downside from Analyst Target:
24.86%
-
Broker Call:
8
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
<0%
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for ASCLETIS-B
| Date | Reported EPS |
|---|
| 2024-08-29 | - |
| 2024-03-24 | - |
| 2023-08-20 | - |
| 2023-03-18 | - |
| 2022-08-21 | - |
| 2022-03-20 | - |
| 2021-08-25 | - |
| 2021-03-29 | - |
| 2021-03-28 | - |
| 2020-08-27 | - |
| 2020-03-23 | - |
| 2019-08-28 | - |
| 2019-03-23 | - |
| 2018-08-31 | - |
| 2018-07-19 | - |
📰 Related News & Research
No related articles found for "ascletisb".
